New Clinical Data On Medtronic Transcatheter Heart Valves Featured In More Than 25 Presentations At TCT 2009

With the promise of percutaneous treatments for patients with diseased heart valves growing, Medtronic, Inc. (NYSE: MDT), announced that more presentations than ever before - at least 25 - on the company's portfolio of unique transcatheter valves will be presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009, the world's premier annual meeting for interventional cardiologists.